HEAL Initiative: Development of Therapies and Technologies Directed at Enhanced Pain Management (R41/R42 Clinical Trial Not Allowed)
The purpose of this Funding Opportunity Announcement (FOA) aims to speed scientific solutions to stem the national opioid public health crisis by supporting the development of therapies and technologies directed at enhanced pain management through the Small Business Technology Transfer (STTR) program. This FOA is focused on applications directed at improving pain treatment, including the development of new non-addictive medications and devices and objective pain measurement. In addition, NIH is interested in new screening tools and models focused specifically on pain and development of pain therapies.RFA-NS-20-009 (Source:...
Source: NIDDK Funding Opportunities - October 4, 2019 Category: Endocrinology Source Type: funding
HEAL Initiative: Development of Therapies and Technologies Directed at Enhanced Pain Management (R41/R42 Clinical Trial Required)
The purpose of this Funding Opportunity Announcement (FOA) aims to speed scientific solutions to stem the national opioid public health crisis by supporting the development of therapies and technologies directed at enhanced pain management through the Small Business Technology Transfer (STTR) program. This FOA is focused on applications directed at improving pain treatment, including the development of new non-addictive medications and devices and objective pain measurement. In addition, NIH is interested in new screening tools and models focused specifically on pain and development of pain therapies.RFA-NS-20-008 (Source:...
Source: NIDDK Funding Opportunities - October 4, 2019 Category: Endocrinology Source Type: funding
Limited Competition for the Accelerating Medicines Partnership (AMP) in Type 2 Diabetes Knowledge Portal (UM1 Clinical Trial Not Allowed)
This Funding Opportunity Announcement (FOA) invites an application from the current awardee institution of the Accelerating Medicines Partnership in Type 2 Diabetes Knowledge Portal (AMP T2D KP). The AMP T2D program is a collaborative partnership between the NIH, pharmaceutical companies, and nonprofit organizations to develop new models for identifying and validating promising biological targets to serve as biomarkers and/or for drug discovery (www.nih.gov/research-training/accelerating-medicines-partnership-amp/type-2-diabetes). This is a one-time FOA to provide funds to the AMP T2D KP to continue the development of the ...
Source: NIDDK Funding Opportunities - September 27, 2019 Category: Endocrinology Source Type: funding
Understanding the Functional Contributions and Mechanisms of Type 2 Diabetes Disease-associated Variants (UM1 Clinical Trial Not Allowed)
This Funding Opportunity Announcement (FOA) encourages applications from integrative teams and individual investigators for large-scale complex multi-disciplinary Functional Genomics Projects (FGPs) to determine the contributions and mechanisms underlying the contribution of risk-associated variants and their downstream effector transcripts for type 2 diabetes (T2D). The intent is to generate knowledge and tools to enable the identification of putative biomarkers and therapeutic targets by future efforts. Genome-wide association studies (GWAS) and other genomic studies of T2D and its complications have found many variants ...
Source: NIDDK Funding Opportunities - September 27, 2019 Category: Endocrinology Source Type: funding
Limited Competition: Continuation of the Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer Coordination and Data Management Center (CPDPC-CDMC) (U01 Clinical Trial Optional)
This Funding Opportunity Announcement (FOA) is a limited invitation for U01 application for one Coordination and Data Management Center (CDMC) to continue the consortium to study Chronic Pancreatitis, Diabetes and Pancreatic Cancer (CPDPC) to conduct and complete ongoing studies on chronic pancreatitis (CP) and factors that increase the risk of pancreatic cancer in patients (children and adults) with CP, pancreatogenic (type 3c) diabetes (T3cDM) and in patients with newly diagnosed diabetes. The CPDPC is composed of several Clinical Centers (CC) and one Coordination and Data Management Center (CDMC) The Consortium since it...
Source: NIDDK Funding Opportunities - September 26, 2019 Category: Endocrinology Source Type: funding
Continuation of the Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer Clinical Centers (CPDPC-CCs) (U01 Clinical Trial Optional)
This Funding Opportunity Announcement (FOA) invites U01 applications for the continuation of the consortium to study Chronic Pancreatitis, Diabetes and Pancreatic Cancer (CPDPC) to conduct and complete ongoing studies on chronic pancreatitis (CP) and factors that increase the risk of pancreatic cancer in patients (children and adults) with CP, pancreatogenic (type 3c) diabetes (T3cDM) and in patients with newly diagnosed diabetes. The CPDPC is composed of several Clinical Centers (CC) and one Coordination and Data Management Center (CDMC) The Consortium since its establishment in Fall 2015 has conducted longitudinal clinic...
Source: NIDDK Funding Opportunities - September 26, 2019 Category: Endocrinology Source Type: funding
Notice of Special Interest: Nutrigenetics and Nutrigenomics Approaches for Nutrition Research
The purpose of this Notice of Special Interest is to foster collaborative research between nutrition researchers and experts in omics technologies and encourages applications that employ nutrigenetics and/or nutrigenomics approaches to basic, translational and clinical nutrition research. Collaboration between investigators with demonstrated expertise in nutrition research and omics techniques is highly encouraged.Padma Maruvada, Ph.D. | NOT-DK-19-019 (Source: NIDDK Funding Opportunities)
Source: NIDDK Funding Opportunities - September 25, 2019 Category: Endocrinology Source Type: funding
NIDDK Hematology Central Coordinating Center (U24 Clinical Trial Not Allowed)
This Funding Opportunity Announcement (FOA) requests applications for the Hematology Central Coordinating Center (HCCC) for the NIDDK Hematology Centers Program. The HCCC is expected to work collaboratively with 4-5 Cooperative Centers of Excellence in Hematology (CCEHs) as part of the NIDDK Hematology Centers Program and serve as a national resource for the larger nonmalignant hematology research community. The HCCC will provide central administrative and communications support for the NIDDK Hematology Centers Program and operate a Pilot and Feasibility Program, supporting pilot research studies that will lead to larger r...
Source: NIDDK Funding Opportunities - September 19, 2019 Category: Endocrinology Source Type: funding
Bioinformatics Interdisciplinary Postdoctoral Fellowship in Diabetes, Endocrinology and Metabolic Diseases (F32)
This Funding Opportunity Announcement (FOA) does not allow applicants to propose to lead an independent clinical trial, but does allow applicants to propose research experience in a clinical trial led by a sponsor or co-sponsor.Arthur L. Castle, Ph.D. | PAR-19-379 (Source: NIDDK Funding Opportunities)
Source: NIDDK Funding Opportunities - September 16, 2019 Category: Endocrinology Source Type: funding
Bioinformatics Interdisciplinary Predoctoral Fellowship in Diabetes, Endocrinology and Metabolic Diseases (F31)
This Funding Opportunity Announcement (FOA) does not allow applicants to propose to lead an independent clinical trial, but does allow applicants to propose research experience in a clinical trial led by a sponsor or co-sponsor.Arthur L. Castle, Ph.D. | PAR-19-378 (Source: NIDDK Funding Opportunities)
Source: NIDDK Funding Opportunities - September 16, 2019 Category: Endocrinology Source Type: funding
NIDDK Cooperative Centers of Excellence in Hematology (U54 Clinical Trial Not Allowed)
The purpose of this Funding Opportunity Announcement is to invite U54 cooperative agreement applications for Cooperative Centers of Excellence in Hematology (CCEH). The NIDDK Hematology Centers Program is designed to increase access to critical research resources and collaboration in the national multidisciplinary research effort to combat nonmalignant hematologic diseases and to study normal hematopoiesis. In addition, it aims to improve cost-effectiveness of preparing critical reagents, maintaining state-of-the-art resources, and running multi-step molecular biologic assays. Each CCEH will support a minimum of three Biom...
Source: NIDDK Funding Opportunities - September 12, 2019 Category: Endocrinology Source Type: funding
Limited Competition: Small Grant Program for NIDDK K01/K08/K23/K25 Recipients (R03 Clinical Trial Optional)
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) announces a program that provides NIDDK-supported K01, K08, K23, and K25 recipients the opportunity to apply for Small Grant (R03) support at some point during the latter years of their award period of their K award. Through the use of this mechanism, the NIDDK is seeking to enhance the capability of its K01, K08, K23, and K25 award recipients to conduct research as they complete their transition to fully independent investigator status. The R03 grant mechanism supports different types of projects, including pilot and feasibility studies; secondar...
Source: NIDDK Funding Opportunities - September 9, 2019 Category: Endocrinology Source Type: funding
Prevention of Lower Urinary Tract Symptoms (PLUS) Research Consortium Scientific and Data Coordinating Center (U24 Clinical Trial Optional)
The Prevention of Lower Urinary tract Symptoms (PLUS) Research Consortium will use qualitative and quantitative strategies to conduct collaborative, transdisciplinary studies to establish the scientific basis for future intervention studies to promote bladder health and prevent lower urinary tract symptoms (LUTS) and associated bladder conditions such as bladder infections, urinary incontinence, voiding dysfunction, overactive bladder and interstitial cystitis/bladder pain syndrome in adolescent and adult women across the life course. The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for ...
Source: NIDDK Funding Opportunities - September 6, 2019 Category: Endocrinology Source Type: funding
Prevention of Lower Urinary Tract Symptoms (PLUS) Research Consortium Clinical Research Centers (U01 Clinical Trial Optional)
The Prevention of Lower Urinary tract Symptoms (PLUS) Research Consortium will use qualitative and quantitative strategies to conduct collaborative, transdisciplinary studies to establish the scientific basis for future intervention studies to promote bladder health and prevent lower urinary tract symptoms (LUTS) and associated bladder conditions such as bladder infections, urinary incontinence, voiding dysfunction, overactive bladder and interstitial cystitis/bladder pain syndrome in adolescent and adult women across the life course. This FOA is to invite applications for Clinical Research Centers to build on foundational...
Source: NIDDK Funding Opportunities - September 6, 2019 Category: Endocrinology Source Type: funding
Notice of Special Interest: Administrative Supplements to Support Emerging Physician-Scientists to Develop Research Expertise in Diabetes, Endocrinology and Metabolic Diseases
The purpose of the NIDDK ’s Division of Diabetes, Endocrinology and Metabolic Diseases (DDEMD) Administrative Supplement Program is to enable additional clinical perspectives to be brought to on-going research projects within the Division's mission and to enhance the research expertise of selected physicians. The program will provide supplementary funds to support advanced research opportunities for exceptional emerging physician-scientists (hereafter, "candidates") holding the MD or equivalent or MD/PhD degrees, and who are early in their research careers.Carol R. Haft, Ph.D. | NOT-DK-19-015 (Source: NIDDK Funding Opportunities)
Source: NIDDK Funding Opportunities - September 4, 2019 Category: Endocrinology Source Type: funding
